JP2023520207A5 - - Google Patents

Info

Publication number
JP2023520207A5
JP2023520207A5 JP2022559580A JP2022559580A JP2023520207A5 JP 2023520207 A5 JP2023520207 A5 JP 2023520207A5 JP 2022559580 A JP2022559580 A JP 2022559580A JP 2022559580 A JP2022559580 A JP 2022559580A JP 2023520207 A5 JP2023520207 A5 JP 2023520207A5
Authority
JP
Japan
Prior art keywords
alkyl
tautomer
compound
ring
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022559580A
Other languages
English (en)
Japanese (ja)
Other versions
JP7733670B2 (ja
JP2023520207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025591 external-priority patent/WO2021203007A1/en
Publication of JP2023520207A publication Critical patent/JP2023520207A/ja
Publication of JP2023520207A5 publication Critical patent/JP2023520207A5/ja
Application granted granted Critical
Publication of JP7733670B2 publication Critical patent/JP7733670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559580A 2020-04-03 2021-04-02 アルファ1-アンチトリプシンのモジュレーター Active JP7733670B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004713P 2020-04-03 2020-04-03
US63/004,713 2020-04-03
PCT/US2021/025591 WO2021203007A1 (en) 2020-04-03 2021-04-02 Substituted 5-hydroxyindole compounds as modulators of alpha-1 antitrypsin

Publications (3)

Publication Number Publication Date
JP2023520207A JP2023520207A (ja) 2023-05-16
JP2023520207A5 true JP2023520207A5 (enExample) 2024-04-10
JP7733670B2 JP7733670B2 (ja) 2025-09-03

Family

ID=76444526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559580A Active JP7733670B2 (ja) 2020-04-03 2021-04-02 アルファ1-アンチトリプシンのモジュレーター

Country Status (7)

Country Link
US (1) US20230339915A1 (enExample)
EP (1) EP4126817A1 (enExample)
JP (1) JP7733670B2 (enExample)
CN (1) CN115916749B (enExample)
AU (1) AU2021246104A1 (enExample)
CA (1) CA3177524A1 (enExample)
WO (1) WO2021203007A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CA3177531A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ1-アンチトリプシンのモジュレーター
EP4188931A2 (en) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
WO2022104353A1 (en) 2020-11-12 2022-05-19 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
CN117384133A (zh) * 2023-10-11 2024-01-12 内蒙古益泽制药有限公司 一种2-溴-1-(吡啶-2-基)吲哚化合物及其制备方法
WO2026136445A1 (en) 2024-12-17 2026-06-25 Sub21, Inc. A1at modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US8097644B2 (en) * 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
JP5107589B2 (ja) * 2007-02-13 2012-12-26 旭化成株式会社 インドール誘導体
RS54165B1 (sr) * 2008-04-16 2015-12-31 Karo Bio Ab Novi ligandi za estrogenski receptor

Similar Documents

Publication Publication Date Title
JP2021513967A5 (enExample)
JP2022545359A5 (enExample)
JP2023500611A5 (enExample)
JP2024050527A5 (enExample)
ES2377947T3 (es) Compuestos de pirimidina como inhibidores de la interleucina 12 (IL-12)
JP2024521895A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2021534124A5 (enExample)
CA2359115A1 (en) Acyl derivatives which treat vla-4 related disorders
JP2010519304A5 (enExample)
JP2012530703A5 (enExample)
JP2022544714A5 (enExample)
RU2005116254A (ru) Производные пиридопирролизина и пиридоиндолизина
CA2486537A1 (en) 4-(substituted cycloalkylmethyl)imidazole-2-thiones, 4-(substituted cycloalkenylmethyl)imidazole-2-thiones, 4-(substituted cycloalkylmethyl)imidazol-2-ones and 4-(substituted cycloalkenylmethyl)imidazol-2-ones and related compounds
JP2931410B2 (ja) 置換ベンズアミジン類、その製法及びそれらの医薬品としての使用
JP2024544060A5 (enExample)
JP2025505644A5 (enExample)
HUP0301562A2 (hu) Új oxazolidinonszármazékok és eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények
JP2002526501A5 (enExample)
KR927003556A (ko) 이방향족 치환된 aids 치료 화합물
JP2023520395A5 (enExample)
JP2021534097A5 (enExample)
JP2025505200A5 (enExample)
JP2019507114A5 (enExample)
RU2007143966A (ru) Конденсированные гетероциклические соединения